---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-20T15:26:07.936513'
end_time: '2026-02-20T15:34:01.809101'
duration_seconds: 473.87
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: NPM1
  gene_symbol: NPM1
  uniprot_accession: P06748
  protein_description: 'RecName: Full=Nucleophosmin; Short=NPM; AltName: Full=Nucleolar
    phosphoprotein B23; AltName: Full=Nucleolar protein NO38; AltName: Full=Numatrin;'
  gene_info: Name=NPM1 {ECO:0000312|HGNC:HGNC:7910}; Synonyms=NPM;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the nucleoplasmin family. .
  protein_domains: NPM1_C. (IPR032569); Nucleoplasmin. (IPR004301); Nucleoplasmin_core_dom.
    (IPR024057); Nucleoplasmin_core_dom_sf. (IPR036824); NPM1-C (PF16276)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 26
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P06748
- **Protein Description:** RecName: Full=Nucleophosmin; Short=NPM; AltName: Full=Nucleolar phosphoprotein B23; AltName: Full=Nucleolar protein NO38; AltName: Full=Numatrin;
- **Gene Information:** Name=NPM1 {ECO:0000312|HGNC:HGNC:7910}; Synonyms=NPM;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the nucleoplasmin family. .
- **Key Domains:** NPM1_C. (IPR032569); Nucleoplasmin. (IPR004301); Nucleoplasmin_core_dom. (IPR024057); Nucleoplasmin_core_dom_sf. (IPR036824); NPM1-C (PF16276)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NPM1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NPM1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NPM1** (gene ID: NPM1, UniProt: P06748) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P06748
- **Protein Description:** RecName: Full=Nucleophosmin; Short=NPM; AltName: Full=Nucleolar phosphoprotein B23; AltName: Full=Nucleolar protein NO38; AltName: Full=Numatrin;
- **Gene Information:** Name=NPM1 {ECO:0000312|HGNC:HGNC:7910}; Synonyms=NPM;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the nucleoplasmin family. .
- **Key Domains:** NPM1_C. (IPR032569); Nucleoplasmin. (IPR004301); Nucleoplasmin_core_dom. (IPR024057); Nucleoplasmin_core_dom_sf. (IPR036824); NPM1-C (PF16276)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NPM1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NPM1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NPM1** (gene ID: NPM1, UniProt: P06748) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive research report: Human NPM1 (nucleophosmin; UniProt P06748)

1. Target verification and scope

This report concerns human nucleophosmin (NPM1; synonyms B23/NO38/numatrin), a 294-aa (~37 kDa) nucleoplasmin-family protein (UniProt P06748 context) whose best-characterized cellular role is as an abundant nucleolar organizer/chaperone that supports ribosome biogenesis and nucleolar integrity, in part via liquid–liquid phase separation (LLPS), and whose most prominent clinical relevance is NPM1-mutated acute myeloid leukemia (AML) with cytoplasmic NPM1 (“NPM1c+”). (taha2024nucleophosminanucleolar pages 1-3, taha2024nucleophosminanucleolar pages 3-4)

2. Key concepts and definitions (current understanding)

2.1 Nucleolar organization and the granular component (GC)

The nucleolus is a membrane-less nuclear compartment where rRNA transcription/processing and ribosome subunit assembly occur; within the nucleolus, NPM1 is predominantly enriched in the granular component (GC), a region linked to late stages of pre-rRNA processing and ribosomal subunit maturation. (taha2024nucleophosminanucleolar pages 4-6)

2.2 Liquid–liquid phase separation (LLPS) and NPM1 as a nucleolar scaffold

NPM1 is widely viewed as a major driver of nucleolar LLPS, forming homotypic droplets and heterotypic droplets with arginine-rich proteins and/or rRNA; these condensate properties help explain how NPM1 contributes to nucleolar structure and ribosome-production capacity. (okuwaki2023thestabilityof pages 1-7, taha2024nucleophosminanucleolar pages 4-6)

2.3 Chaperone concepts applied to NPM1

NPM1 is described as a multifunctional molecular chaperone for both proteins and nucleic acids. In practice this includes histone chaperone activity (supporting nucleosome formation and chromatin remodeling) and broader protein/nucleic-acid chaperoning during stress and nucleolar/ribosome assembly. (taha2024nucleophosminanucleolar pages 1-3, taha2024nucleophosminanucleolar pages 10-12)

3. NPM1 protein architecture, domains, and structure-function links

3.1 Modular domain organization

Across recent reviews, NPM1 is described as a modular protein with: (i) an N-terminal oligomerization domain (OD) that supports assembly into pentamers and higher-order oligomers; (ii) a central acidic/disordered region that contributes to histone binding and regulation of interactions; and (iii) a C-terminal globular nucleic-acid-binding region (also described as an RNA-recognition domain) that includes nucleolar localization determinants (NoLS) and aromatic residues important for correct folding and nucleolar targeting. (taha2024nucleophosminanucleolar pages 3-4, okuwaki2023thestabilityof pages 1-7, chin2023targetingandmonitoring pages 2-5)

A schematic view of this domain architecture and its disruption in AML-associated mutants is shown in Chin et al. (2023). (chin2023targetingandmonitoring media 7f713754, chin2023targetingandmonitoring media 4ef58d28)

3.2 Oligomerization and control of condensate material properties (recent mechanistic insight)

A 2023 mechanistic study links oligomer stability to the “quality” (material properties) of NPM1-driven liquid droplets: destabilizing oligomers (e.g., by altering acidic disordered regions or phosphomimetic changes at Ser125) increased droplet fluidity, supporting a model where post-translationally tuned oligomer stability helps regulate nucleolar dynamics across the cell cycle. (okuwaki2023thestabilityof pages 1-7)

4. Subcellular localization and trafficking

4.1 Basal localization and shuttling

NPM1 is described as primarily nucleolar but dynamically shuttling between the nucleolus, nucleoplasm, and cytoplasm via nuclear localization signals (NLSs) and nuclear export signals (NESs). A key export pathway involves CRM1/XPO1 and RAN; one NES (often described as NES2) is highlighted as important for export control and is also discussed in relation to centrosome association. (taha2024nucleophosminanucleolar pages 3-4, taha2024nucleophosminanucleolar pages 4-6)

4.2 Stress-responsive relocalization

NPM1 is considered a stress sensor/regulator: multiple stresses (e.g., irradiation, UV, oxidative stress) alter NPM1 phosphorylation and/or localization; oxidation/S-glutathionylation at Cys275 is described as a trigger for release from the nucleolus to the nucleoplasm during nucleolar stress responses. (taha2024nucleophosminanucleolar pages 4-6, taha2024nucleophosminanucleolar pages 1-3)

5. Primary cellular functions and pathways (functional annotation narrative)

5.1 Ribosome biogenesis (central function)

NPM1’s best-supported primary cellular role is to support ribosome biogenesis and nucleolar structure.

Mechanistically, NPM1 is reported to regulate late pre-rRNA processing and ribosomal subunit assembly in the GC and to directly bind and assist nuclear export of ribosomal protein L5 (rpL5). Experimental perturbation of NPM1 impairs export of rpL5 and 5S rRNA, and reduces proliferation, consistent with an essential role in sustaining ribosome output. (taha2024nucleophosminanucleolar pages 4-6)

NPM1 is also described as an endoribonuclease contributing to processing steps toward mature 28S rRNA, and as a scaffold interacting with multiple ribosomal proteins. (chin2023targetingandmonitoring pages 2-5, taha2024nucleophosminanucleolar pages 3-4)

5.2 Chromatin and histone chaperone functions

NPM1 is described as a histone-binding protein whose acidic stretches can “mimic DNA,” supporting preferential binding to histone H3 and promoting nucleosome formation and chromatin decondensation. These functions provide a mechanistic route for NPM1 to influence transcription and genome organization, including nucleolus-associated chromatin states. (taha2024nucleophosminanucleolar pages 3-4)

5.3 Genome stability and DNA repair (recent review emphasis)

NPM1 has increasingly been highlighted as participating in DNA damage responses and repair pathway execution, including scaffolding/interaction with DNA repair factors and regulation by phosphorylation states; NPM1 is also described as interacting with p53/HDM2 regulatory circuits in the context of stress and genome stability. (taha2024nucleophosminanucleolar pages 4-6, taha2024nucleophosminanucleolar pages 10-12)

6. Regulation by post-translational modifications (PTMs)

Recent reviews emphasize that phosphorylation, acetylation, ubiquitination, SUMOylation, and oxidative modifications can regulate NPM1 oligomeric state, localization, and functional outputs.

Phosphorylation: multiple residues are highlighted as functionally important, including Ser4 (linked to centrosome/centriole duplication regulation), Ser48 (affecting localization), Ser125 (linked to oligomer stability/condensate properties), and Thr199 (linked to centrosome duplication and mitotic control and reduced RNA binding). Additional mitosis-linked phosphorylation sites (e.g., Thr234/Thr237) are associated with nucleolar disassembly/detachment. (taha2024nucleophosminanucleolar pages 4-6, okuwaki2023thestabilityof pages 1-7, taha2024nucleophosminanucleolar pages 3-4)

SUMOylation/ubiquitination/acetylation: NPM1 SUMOylation and deSUMOylation (e.g., SENP3-regulated) are described as influencing ribosome biogenesis and other nuclear functions; acetylation is described as favoring nucleoplasmic localization and modulating transcriptional activation; ubiquitination pathways (e.g., BRCA1–BARD1-related) are discussed as modulating NPM1 stability. (taha2024nucleophosminanucleolar pages 3-4, taha2024nucleophosminanucleolar pages 12-13)

7. Recent developments and latest research directions (2023–2024)

7.1 LLPS as a unifying framework for nucleolar homeostasis

The 2023 mechanistic linkage between NPM1 oligomer stability and droplet fluidity provides a concrete route by which phosphorylation and disordered-region charge patterning could tune nucleolar condensate behavior. This helps connect classical “nucleolar protein/chaperone” views of NPM1 to modern condensate/phase-separation models. (okuwaki2023thestabilityof pages 1-7)

7.2 Emerging view of NPM1 as a genome–nucleolus interface factor

Recent sources increasingly discuss NPM1 beyond ribosome biogenesis, emphasizing roles in genome organization and repair and positioning NPM1 as a hub integrating stress signals, chromatin regulation, and nucleolar function. (taha2024nucleophosminanucleolar pages 10-12, taha2024nucleophosminanucleolar pages 4-6)

8. Disease relevance and real-world implementations (focus: NPM1-mutated AML)

8.1 Defining lesion and epidemiology

NPM1-mutated AML is described as the largest molecular subgroup of adult AML, accounting for ~30–35% of adult cases; it is enriched in normal-karyotype AML (~50–60%) and is less frequent in children (~2–8%). (Falini & Dillon, Blood Cancer Discovery; publication date: Dec 2024; https://doi.org/10.1158/2643-3230.bcd-23-0144) (falini2024criteriafordiagnosis pages 1-2)

At the protein level, common exon 12 frameshift mutations disrupt the C-terminal fold/NoLS (including loss of key aromatic residues such as W288/W290) and introduce/strengthen nuclear export, shifting NPM1 to the cytoplasm (NPM1c+), a hallmark that can be visualized by immunohistochemistry and summarized schematically in recent reviews. (chin2023targetingandmonitoring pages 2-5, chin2023targetingandmonitoring media 7f713754)

8.2 Diagnostics and classification (2023–2024 perspective)

Recent expert reviews highlight changing classification criteria: WHO5 and ICC both treat NPM1 mutation as AML-defining, but may differ on blast-count thresholds, creating potential diagnostic discordance. (Patel, Pathobiology; publication date: Mar 2024; https://doi.org/10.1159/000530253) (patel2024npm1mutatedacutemyeloid pages 4-5)

8.3 Molecular monitoring / measurable residual disease (MRD) as a clinical tool

A key practical implementation is serial monitoring of mutant NPM1 transcripts. A 2024 expert review emphasizes that NPM1 mutations are AML-specific and (as framed by the authors) absent from preleukemic clonal hematopoiesis, making them particularly suitable MRD targets; ELN guidelines mandate NPM1 (and FLT3) testing for risk stratification and increasingly recommend MRD integration into management decisions. (Falini & Dillon, Dec 2024; https://doi.org/10.1158/2643-3230.bcd-23-0144) (falini2024criteriafordiagnosis pages 6-7, falini2024criteriafordiagnosis pages 1-2)

Methodologically, RT-qPCR is positioned as the established standard; ddPCR is highlighted for high sensitivity and practical quantification of rare mutant types without reliance on standard curves, whereas NGS-based MRD is described as less standardized and often less sensitive, especially from genomic DNA, and recommended mainly in clinical-trial contexts. (falini2024criteriafordiagnosis pages 6-7)

8.4 Outcomes data and statistics from recent studies

Venetoclax-based nonintensive therapy (real-world cohort, 2024): In 76 previously untreated NPM1-mutated AML patients achieving CR/CRi on venetoclax + HMA or venetoclax + LDAC, 58% achieved bone marrow MRD negativity; cumulative MRD negativity by cycles 2, 4, and 6 was 25%, 47%, and 50%, respectively. Patients who were MRD-negative by end of cycle 4 had 2-year OS 84% versus 46% if MRD-positive, and among those who electively stopped therapy in MRD-negative remission, 2-year treatment-free remission was 88%. (Othman et al., Blood; publication date: Jan 2024; https://doi.org/10.1182/blood.2023021579) (othman2024molecularmrdis pages 5-6)

Relapsed/refractory AML outcomes (2023): In a large single-center retrospective cohort of 1,722 relapsed/refractory AML patients, 12% (206) had NPM1c. Adding venetoclax to salvage regimens in NPM1c disease was associated with improved outcomes (median RFS 15.8 vs 4.6 months; median OS 14.7 vs 5.9 months). (Issa et al., Blood Advances; publication date: Mar 2023; https://doi.org/10.1182/bloodadvances.2022008316) (issa2023clinicaloutcomesassociated pages 1-2)

8.5 Targeted therapies and emerging strategies (expert synthesis)

Recent expert syntheses emphasize that NPM1c biology is linked to HOX/MEIS programs and that this dependency may help explain responses to emerging agents such as menin inhibitors and second-generation XPO1 inhibitors. A 2024 diagnostic/MRD review also cites clinical activity of the menin inhibitor revumenib in NPM1-mutated AML (reported 21% complete remissions, often with MRD negativity). (Falini & Dillon, Dec 2024; https://doi.org/10.1158/2643-3230.bcd-23-0144) (falini2024criteriafordiagnosis pages 1-2)

9. Expert opinions and interpretive analysis (authoritative sources)

9.1 NPM1 as an MRD “ideal target” and a decision tool—yet with implementation cautions

Falini & Dillon (2024) argue that NPM1 is an excellent MRD marker because it is common, AML-specific, and dynamically tracks disease burden; they also caution about inter-laboratory false positives and the need for rigorous assay validation and harmonization, and they note that MRD-guided transplant decisions remain incompletely supported by direct evidence in some risk subsets. (falini2024criteriafordiagnosis pages 6-7)

9.2 MRD negativity as a functional biomarker in venetoclax regimens

Othman et al. (2024) interpret early MRD negativity during venetoclax-based therapy as a strong prognostic marker that may enable treatment de-escalation/cessation strategies for selected patients, while emphasizing the need for prospective trials because indefinite therapy is common and cure is not proven. (othman2024molecularmrdis pages 8-9)

10. Limitations of the present evidence extraction

Quantitative biophysical constants (e.g., binding affinities, LLPS saturation concentrations, FRAP recovery half-times) were not present in the extracted text snippets available here; the most direct mechanistic quantitative directionality obtained was that droplet fluidity increases when oligomer stability decreases (e.g., Ser125 phosphomimetics), supporting regulation of nucleolar material properties by NPM1 oligomerization. (okuwaki2023thestabilityof pages 1-7)

11. Key citations (2023–2024 prioritized)

- Taha MS, Ahmadian MR. “Nucleophosmin: A Nucleolar Phosphoprotein Orchestrating Cellular Stress Responses.” Cells. July 2024. https://doi.org/10.3390/cells13151266 (taha2024nucleophosminanucleolar pages 1-3, taha2024nucleophosminanucleolar pages 3-4)
- Okuwaki M, et al. “The stability of NPM1 oligomers regulated by acidic disordered regions controls the quality of liquid droplets.” bioRxiv. Jan 2023. https://doi.org/10.1101/2023.01.23.525122 (okuwaki2023thestabilityof pages 1-7)
- Chin L, et al. “Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation.” Int J Mol Sci. Feb 2023. https://doi.org/10.3390/ijms24043161 (chin2023targetingandmonitoring pages 2-5, chin2023targetingandmonitoring media 7f713754)
- Falini B, Dillon R. “Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.” Blood Cancer Discovery. Dec 2024. https://doi.org/10.1158/2643-3230.bcd-23-0144 (falini2024criteriafordiagnosis pages 1-2, falini2024criteriafordiagnosis pages 6-7)
- Patel SS. “NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.” Pathobiology. Mar 2024. https://doi.org/10.1159/000530253 (patel2024npm1mutatedacutemyeloid pages 4-5)
- Othman J, et al. “Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.” Blood. Jan 2024. https://doi.org/10.1182/blood.2023021579 (othman2024molecularmrdis pages 5-6)
- Issa GC, et al. “Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.” Blood Advances. Mar 2023. https://doi.org/10.1182/bloodadvances.2022008316 (issa2023clinicaloutcomesassociated pages 1-2)


References

1. (taha2024nucleophosminanucleolar pages 1-3): Mohamed S. Taha and Mohammad Reza Ahmadian. Nucleophosmin: a nucleolar phosphoprotein orchestrating cellular stress responses. Cells, 13:1266, Jul 2024. URL: https://doi.org/10.3390/cells13151266, doi:10.3390/cells13151266. This article has 19 citations.

2. (taha2024nucleophosminanucleolar pages 3-4): Mohamed S. Taha and Mohammad Reza Ahmadian. Nucleophosmin: a nucleolar phosphoprotein orchestrating cellular stress responses. Cells, 13:1266, Jul 2024. URL: https://doi.org/10.3390/cells13151266, doi:10.3390/cells13151266. This article has 19 citations.

3. (taha2024nucleophosminanucleolar pages 4-6): Mohamed S. Taha and Mohammad Reza Ahmadian. Nucleophosmin: a nucleolar phosphoprotein orchestrating cellular stress responses. Cells, 13:1266, Jul 2024. URL: https://doi.org/10.3390/cells13151266, doi:10.3390/cells13151266. This article has 19 citations.

4. (okuwaki2023thestabilityof pages 1-7): Mitsuru Okuwaki, Shin-Ichiro Ozawa, Shuhei Ebine, Motoki Juichi, Tadanobu Umeki, Kazuki Niioka, Taiyo Kikuchi, and Nobutada Tanaka. The stability of npm1 oligomers regulated by acidic disordered regions controls the quality of liquid droplets. bioRxiv, Jan 2023. URL: https://doi.org/10.1101/2023.01.23.525122, doi:10.1101/2023.01.23.525122. This article has 7 citations.

5. (taha2024nucleophosminanucleolar pages 10-12): Mohamed S. Taha and Mohammad Reza Ahmadian. Nucleophosmin: a nucleolar phosphoprotein orchestrating cellular stress responses. Cells, 13:1266, Jul 2024. URL: https://doi.org/10.3390/cells13151266, doi:10.3390/cells13151266. This article has 19 citations.

6. (chin2023targetingandmonitoring pages 2-5): Lynn Chin, Chantelle Ye Gwen Wong, and Harinder Gill. Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (npm1) mutation. International Journal of Molecular Sciences, 24:3161, Feb 2023. URL: https://doi.org/10.3390/ijms24043161, doi:10.3390/ijms24043161. This article has 19 citations.

7. (chin2023targetingandmonitoring media 7f713754): Lynn Chin, Chantelle Ye Gwen Wong, and Harinder Gill. Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (npm1) mutation. International Journal of Molecular Sciences, 24:3161, Feb 2023. URL: https://doi.org/10.3390/ijms24043161, doi:10.3390/ijms24043161. This article has 19 citations.

8. (chin2023targetingandmonitoring media 4ef58d28): Lynn Chin, Chantelle Ye Gwen Wong, and Harinder Gill. Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (npm1) mutation. International Journal of Molecular Sciences, 24:3161, Feb 2023. URL: https://doi.org/10.3390/ijms24043161, doi:10.3390/ijms24043161. This article has 19 citations.

9. (taha2024nucleophosminanucleolar pages 12-13): Mohamed S. Taha and Mohammad Reza Ahmadian. Nucleophosmin: a nucleolar phosphoprotein orchestrating cellular stress responses. Cells, 13:1266, Jul 2024. URL: https://doi.org/10.3390/cells13151266, doi:10.3390/cells13151266. This article has 19 citations.

10. (falini2024criteriafordiagnosis pages 1-2): Brunangelo Falini and Richard Dillon. Criteria for diagnosis and molecular monitoring of <i>npm1</i>-mutated aml. Blood Cancer Discovery, 5:8-20, Dec 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0144, doi:10.1158/2643-3230.bcd-23-0144. This article has 37 citations and is from a peer-reviewed journal.

11. (patel2024npm1mutatedacutemyeloid pages 4-5): Sanjay S. Patel. Npm1-mutated acute myeloid leukemia: recent developments and open questions. Pathobiology, 91:18-29, Mar 2024. URL: https://doi.org/10.1159/000530253, doi:10.1159/000530253. This article has 22 citations and is from a peer-reviewed journal.

12. (falini2024criteriafordiagnosis pages 6-7): Brunangelo Falini and Richard Dillon. Criteria for diagnosis and molecular monitoring of <i>npm1</i>-mutated aml. Blood Cancer Discovery, 5:8-20, Dec 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0144, doi:10.1158/2643-3230.bcd-23-0144. This article has 37 citations and is from a peer-reviewed journal.

13. (othman2024molecularmrdis pages 5-6): Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, and Richard Dillon. Molecular mrd is strongly prognostic in patients with <i>npm1</i>-mutated aml receiving venetoclax-based nonintensive therapy. Blood, 143:336-341, Jan 2024. URL: https://doi.org/10.1182/blood.2023021579, doi:10.1182/blood.2023021579. This article has 71 citations and is from a highest quality peer-reviewed journal.

14. (issa2023clinicaloutcomesassociated pages 1-2): Ghayas C. Issa, Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Musa Yilmaz, Nicholas J. Short, Abhishek Maiti, Koji Sasaki, Lucia Masarova, Sherry Pierce, Koichi Takahashi, Guilin Tang, Sanam Loghavi, Keyur Patel, Michael Andreeff, Kapil Bhalla, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, and Naval Daver. Clinical outcomes associated with <i>npm1</i> mutations in patients with relapsed or refractory aml. Blood Advances, 7:933-942, Mar 2023. URL: https://doi.org/10.1182/bloodadvances.2022008316, doi:10.1182/bloodadvances.2022008316. This article has 54 citations and is from a peer-reviewed journal.

15. (othman2024molecularmrdis pages 8-9): Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, and Richard Dillon. Molecular mrd is strongly prognostic in patients with <i>npm1</i>-mutated aml receiving venetoclax-based nonintensive therapy. Blood, 143:336-341, Jan 2024. URL: https://doi.org/10.1182/blood.2023021579, doi:10.1182/blood.2023021579. This article has 71 citations and is from a highest quality peer-reviewed journal.

## Citations

1. taha2024nucleophosminanucleolar pages 4-6
2. okuwaki2023thestabilityof pages 1-7
3. taha2024nucleophosminanucleolar pages 3-4
4. falini2024criteriafordiagnosis pages 1-2
5. falini2024criteriafordiagnosis pages 6-7
6. othman2024molecularmrdis pages 5-6
7. issa2023clinicaloutcomesassociated pages 1-2
8. othman2024molecularmrdis pages 8-9
9. taha2024nucleophosminanucleolar pages 1-3
10. taha2024nucleophosminanucleolar pages 10-12
11. chin2023targetingandmonitoring pages 2-5
12. taha2024nucleophosminanucleolar pages 12-13
13. https://doi.org/10.1158/2643-3230.bcd-23-0144
14. https://doi.org/10.1159/000530253
15. https://doi.org/10.1182/blood.2023021579
16. https://doi.org/10.1182/bloodadvances.2022008316
17. https://doi.org/10.3390/cells13151266
18. https://doi.org/10.1101/2023.01.23.525122
19. https://doi.org/10.3390/ijms24043161
20. https://doi.org/10.3390/cells13151266,
21. https://doi.org/10.1101/2023.01.23.525122,
22. https://doi.org/10.3390/ijms24043161,
23. https://doi.org/10.1158/2643-3230.bcd-23-0144,
24. https://doi.org/10.1159/000530253,
25. https://doi.org/10.1182/blood.2023021579,
26. https://doi.org/10.1182/bloodadvances.2022008316,